《半日总结》恒指跌135点 科技股吐 瑞声挫逾7%
美股标普500指数及纳指破顶，恒指则未能企稳25,500点并回吐。恒指高开35点，早段曾升69点见25,621点，其後掉头向下，曾跌188点低见25,363点，半日跌135点或0.5%，报25,416点；国指跌76点或0.7%，报10,259点；恒生科技指数跌133点或1.8%，报7,196点。大市半日成交总额716.45亿元，沪、深港通南下交易半日录得净流入金额分别为3.77亿及10.65亿元人民币。
汇控(00005.HK)升1.8%报34.5元，友邦(01299.HK)跌0.7%报78元，港交所(00388.HK)跌1.1%报376.8元。电讯股中移动(00941.HK)跌1.4%，中电信(00728.HK)及联通(00762.HK)各跌1.9%及2.7%。地产股九仓置业(01997.HK)跌3%。此外，中国平安(02318.HK)升0.1%，吉利(00175.HK)升0.9%。
主要科技股方面，腾讯(00700.HK)跌1.6%报539.5元，阿里巴巴(09988.HK)升1.9%报269.4元，美团点评(03690.HK)跌2.7%报258.6元，小米(01810.HK)跌2.6%报17.96元，京东(09618.HK)升0.4%，网易(09999.HK)跌0.5%。其他科技股普遍下跌，平安好医生(01833.HK)、心动(02400.HK)及恒腾网络(00136.HK)各跌2.5%至3.8%，金蝶国际(00268.HK)及微盟(02013.HK)各跌4.6%及5%，阿里健康(00241.HK)跌6.5%。新东方在线(01797.HK)则逆升4%。
手机相关股方面，瑞声(02018.HK)季绩远逊预期遭大行接连下调目标价，早市股价挫7.3%报49.15元。舜宇(02382.HK)跌4.4%。半导体股方面，中芯(00981.HK)平收报25.7元，华虹半导体(01347.HK)跌2.2%。
多只医药股表现较弱，中生制药(01177.HK)跌4.4%，药明生物(02269.HK)跌3.9%，复星医药(02196.HK)、中国中药(00570.HK)及白云山(00874.HK)各跌3.4%、3.1%及2%。内需股方面，康师傅(00322.HK)半年多赚58%获券商上调目标价，股价升10.6%。华润啤酒(00291.HK)、国美(00493.HK)及蒙牛(02319.HK)各跌2%至2.9%，猫眼娱乐(01896.HK)跌3.7%。电动车生产商比亚迪(01211.HK)跌3%。
航空股逆市上扬，国泰航空(00293.HK)升4.7%，国航(00753.HK)、东航(00670.HK)及南航(01055.HK)各升3.4%、4.7%及5.5%。中国飞机租赁(01848.HK)及中银航空租赁(02588.HK)各升2.8%及4.1%。内房股华润置地(01109.HK)、中国金茂(00817.HK)、奥园(03883.HK)及中海外(00688.HK)各跌1.7%至2.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
